Paper39199348
Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.
Gu Y and 6 others. Biomolecules, 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment. Papers, record 39199348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199348
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Drug Delivery Systems | Major topic |
| Humans | |
| Biomimetic Materials | |
| Biomimetics | |
| Animals | |
| Nanomedicine | |
| Nanoparticles | |
| Nanoparticle Drug Delivery System |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82174343 | National Natural Science Foundation of China | PubMed | ||
| 202302 | Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine | PubMed | ||
| CX20230830 | Postgraduate Scientific Research Innovation Project of Hunan Province | PubMed | ||
| S202310541090 | Hunan University students innovation and entrepreneurship training program | PubMed | ||
| D202303017861 | Scientific Research Topics of Hunan Provincial Health and Wellness Commission | PubMed |
Source PubMed
References144
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29408473 | Curcumin marinosomes as promising nano-drug delivery system for lung cancer. | Int J Pharm | 2018 | https://conductscience.org/library/papers/29408473 | PubMed |
| 2 | 28860319 | Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. | Circ Res | 2017 | https://conductscience.org/library/papers/28860319 | PubMed |
| 3 | 37515961 | A erythrocyte-platelet hybrid membrane coated biomimetic nanosystem based on ginsenosides and PFH combined with ultrasound for targeted delivery in thrombus therapy. | Colloids Surf B Biointerfaces | 2023 | https://conductscience.org/library/papers/37515961 | PubMed |
| 4 | 35354074 | Neighborhood-level Social Vulnerability and Prevalence of Cardiovascular Risk Factors and Coronary Heart Disease. | Curr Probl Cardiol | 2023 | https://conductscience.org/library/papers/35354074 | PubMed |
| 5 | 28382729 | Gold nanoparticles in cardiovascular imaging. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2018 | https://conductscience.org/library/papers/28382729 | PubMed |
| 6 | 34236248 | Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment. | Drug Deliv | 2021 | https://conductscience.org/library/papers/34236248 | PubMed |
| 7 | 27544847 | (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice. | Int J Pharm | 2016 | https://conductscience.org/library/papers/27544847 | PubMed |
| 8 | 36898531 | Anti-CXCR2 antibody-coated nanoparticles with an erythrocyte-platelet hybrid membrane layer for atherosclerosis therapy. | J Control Release | 2023 | https://conductscience.org/library/papers/36898531 | PubMed |
| 9 | 36103910 | Stem cell membrane-coated abiotic nanomaterials for biomedical applications. | J Control Release | 2022 | https://conductscience.org/library/papers/36103910 | PubMed |
| 10 | 37527612 | Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials. | Atherosclerosis | 2023 | https://conductscience.org/library/papers/37527612 | PubMed |
| 11 | 32730849 | Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. | Adv Drug Deliv Rev | 2020 | https://conductscience.org/library/papers/32730849 | PubMed |
| 12 | 29700074 | Emerging Role of Precision Medicine in Cardiovascular Disease. | Circ Res | 2018 | https://conductscience.org/library/papers/29700074 | PubMed |
| 13 | 38223291 | Precision cardiac targeting: empowering curcumin therapy through smart exosome-mediated drug delivery in myocardial infarction. | Regen Biomater | 2024 | https://conductscience.org/library/papers/38223291 | PubMed |
| 14 | 31427727 | Counter-regulatory renin-angiotensin system in cardiovascular disease. | Nat Rev Cardiol | 2020 | https://conductscience.org/library/papers/31427727 | PubMed |
| 15 | 35511857 | Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. | Eur Heart J | 2022 | https://conductscience.org/library/papers/35511857 | PubMed |
| 16 | 36924328 | Drug loaded implantable devices to treat cardiovascular disease. | Expert Opin Drug Deliv | 2023 | https://conductscience.org/library/papers/36924328 | PubMed |
| 17 | 38614985 | Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE-/- Mice. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38614985 | PubMed |
| 18 | 36575429 | Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. | J Nanobiotechnology | 2022 | https://conductscience.org/library/papers/36575429 | PubMed |
| 19 | 34286950 | Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics. | ACS Appl Mater Interfaces | 2021 | https://conductscience.org/library/papers/34286950 | PubMed |
| 20 | 32263201 | A novel multifunctional biomimetic Au@BSA nanocarrier as a potential siRNA theranostic nanoplatform. | J Mater Chem B | 2016 | https://conductscience.org/library/papers/32263201 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42909371 | Cell-derived biomimetic nanomedicines: Emerging theranostic platforms for precision management of atherosclerosis. | Theranostics | 2026 | https://conductscience.org/library/papers/42909371 | PubMed |
| 42579251 | Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies. | Discov Nano | 2026 | https://conductscience.org/library/papers/42579251 | PubMed |
| 42333862 | Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. | J Appl Biomed | 2026 | https://conductscience.org/library/papers/42333862 | PubMed |
| 42016346 | Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42016346 | PubMed |
| 41906208 | Biomimetic materials for medical applications. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/41906208 | PubMed |
| 41340638 | Harnessing nature's blueprint: Unlocking the potential of subcellular structure membrane-coated nanosystems for precision medicine. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41340638 | PubMed |
| 41229674 | Macrophage Membrane-Coated Nanocarriers in Myocardial Infarction: A Paradigm Shift in Targeted Cardiac Therapy. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41229674 | PubMed |
| 40909219 | Biomimetic membrane nanotechnology in cerebral ischemic stroke:a promising technology for therapeutic treatment and diagnosis. | Front Bioeng Biotechnol | 2025 | https://conductscience.org/library/papers/40909219 | PubMed |
| 40137371 | Fabrication and Characterization of Immature Porcine Cartilage-Derived Cell Biomembranes. | J Funct Biomater | 2025 | https://conductscience.org/library/papers/40137371 | PubMed |
| 40125442 | How Advanced Is Nanomedicine for Atherosclerosis? | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40125442 | PubMed |
| 40050980 | SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40050980 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39199348
GET https://conductscience.org/api/papers/v1/39199348/references?page=2